| 4/7/2021 |
Invitae to acquire Genosity for $200m, lands $1.15bn investment |
medicaldevice-network.com |
... products, which are designed to enable development and deployment of complex sequencing-based tests, to Invitae’s platform.Invitae said the deal will accelerate the time to market and decentralisation of Invitae’s personalised oncology diagnostics , which include three devices under development that have received breakthrough device designation from the US (FDA).Genosity has already worked with Invitae on a number of projects and clinical research trials in the past ... |
| 3/30/2021 |
Biocept (NASDAQ:BIOC) Announces Quarterly |
Daily Political |
... the stock. Zacks Investment Research downgraded Biocept from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. Biocept Company Profile Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/27/2021 |
Biocept (BIOC) Set to Announce Earnings on Monday |
Daily Political |
... Zacks Investment Research cut shares of Biocept from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. Biocept Company Profile Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/25/2021 |
Clinical Oncology Next Generation Sequencing Market Expanding At A CAGR 14.70% For The Forecast Period From 2021 To 2028: Grand View Research Inc. |
Wordpress.com |
... for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry ... |
| 3/25/2021 |
Clinical Oncology Next Generation Sequencing Market In-Depth Analysis On Technology, Workflow, Application, End-Use, Region And Forecasts To 2028 |
dailygram.com |
... for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry ... |
| 3/23/2021 |
Critical Review: Biocept (NASDAQ:BIOC) & Renalytix AI (NASDAQ:RNLX) |
zolmax.com |
... a potential downside of 25.60%. Given Biocept’s stronger consensus rating and higher possible upside, research analysts clearly believe Biocept is more favorable than Renalytix AI.About BioceptBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/23/2021 |
Inside the Diagnostics Industry: Guardant Health Takes Aim at Exact Sciences’ Leadership of Colorectal Cancer Market |
g2intelligence.com |
... Institute (TGen) for an undisclosed price. Ashion is a CLIA-certified and CAP-accredited sequencing laboratory whose genomic testing assets will bolster Exact’s efforts to enhance its Cologuard product and develop new precision oncology diagnostics for MRD and other cancers. Those Ashion assets include the GEM ExTra comprehensive cancer test, as well as whole-exome, matched germline and transcriptome sequencing capabilities.The Ashion acquisition, which is scheduled to close ... |
| 3/18/2021 |
ACI Global (OTCMKTS:ACGJ) & Biocept (NASDAQ:BIOC) Head to Head Contrast |
rivertonroll.com |
... on 5 of the 9 factors compared between the two stocks.ACI Global Company ProfileThere is no company description available for ACI Global Corp.Biocept Company ProfileBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/16/2021 |
The Ridgway Record |
ridgwayrecord.com |
... fourth quarter and full year 2020 ended December 31, 2020, along with a corporate update.“In a short time, we have transformed Oncocyte from a single-product, development stage company into a commercial stage oncology diagnostics company with a broadening product portfolio and multiple engines of revenue growth,” said Ron Andrews, President and Chief Executive Officer of Oncocyte. “We began to build momentum in the commercialization of our expanding ... |
| 3/16/2021 |
Head to Head Review: ACI Global (OTCMKTS:ACGJ) and Biocept (NASDAQ:BIOC) |
slatersentinel.com |
... on 5 of the 9 factors compared between the two stocks.ACI Global Company ProfileThere is no company description available for ACI Global Corp.Biocept Company ProfileBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/16/2021 |
ACI Global (OTCMKTS:ACGJ) & Biocept (NASDAQ:BIOC) Head-To-Head Contrast |
Mayfield Recorder |
... on 5 of the 9 factors compared between the two stocks.ACI Global Company ProfileThere is no company description available for ACI Global Corp.Biocept Company ProfileBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 3/11/2021 |
Eurofins Viracor BioPharma Launches PanCancerIQ Comprehensive Genomic Profiling Service to Advance Precision Oncology Clinical Drug Development |
pr.com |
... genomic biomarkers, including universal markers such as TMB, MSI and NTRK-fusions contributing to sample consolidation, reducing patient re-biopsy, as well as potentially increasing assignment of targeted therapy.According to Viracor’s Director of Oncology Diagnostics , Karina Eterovic, PhD., "The PanCancerIQ assay, combined with our broader analytical testing solutions, can help accelerate precision oncology studies by screening patients for recruitment in genomically informed trials, unveiling potential new markers of resistance ... |
| 3/11/2021 |
The Ridgway Record |
ridgwayrecord.com |
... biomarkers, including universal markers such as TMB, MSI and NTRK-fusions contributing to sample consolidation, reducing patient re-biopsy, as well as potentially increasing assignment of targeted therapy.According to Viracor’s Director of Oncology Diagnostics , Karina Eterovic, PhD., "The PanCancerIQ assay, combined with our broader analytical testing solutions, can help accelerate precision oncology studies by screening patients for recruitment in genomically informed trials, unveiling potential new markers of resistance ... |
| 3/11/2021 |
Global Medical Imaging Technologies for Oncology Diagnostics Market Size, Share, Analytical Overview, Future Trends, Demand, Historical Analysis, Growth Factors and Forecast to 2026 |
sunrisenigeria.com |
... reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Medical Imaging Technologies for Oncology Diagnostics market. Global Medical Imaging Technologies for Oncology Diagnostics Market: Regional Analysis The report offers in-depth assessment of the growth and other aspects of the Medical Imaging Technologies for Oncology Diagnostics market in important ... |
| 3/11/2021 |
Lee's Summit, MO, 11, Eu |
wapakdailynews.com |
... biomarkers, including universal markers such as TMB, MSI and NTRK-fusions contributing to sample consolidation, reducing patient re-biopsy, as well as potentially increasing assignment of targeted therapy.According to Viracor’s Director of Oncology Diagnostics , Karina Eterovic, PhD., "The PanCancerIQ assay, combined with our broader analytical testing solutions, can help accelerate precision oncology studies by screening patients for recruitment in genomically informed trials, unveiling potential new markers of resistance ... |
| 3/9/2021 |
The Ridgway Record |
ridgwayrecord.com |
... cells2.0.2 Adaptive immune system2.0.2.1 Lymphocytes2.0.2.2 Killer T cells2.0.2.3 Helper T cells2.0.2.4 Gamma delta T cells2.0.2.5 B lymphocytes and antibodies2.0.3 Tumor immunology - the immune surveillance system2.1 Immuno Oncology Diagnostics 2.1.1 Checkpoint Assays2.1.2 Cytokine Assays2.1.3 Genomic Germline2.1.4 Genomic Tumour2.1.5 Tumor Microenviroment3. Industry Overview3.1 Players in a Dynamic Market3.1.1 Academic Research Lab3.1.2 Diagnostic Test Developer3.1.3 Genomic ... |
| 3/8/2021 |
Global Immuno-Oncology Diagnostics Market Forecast & Analysis 2021-2025 with COVID-19 Impact and Updates – ResearchAndMarkets.com |
financialbuzz.com |
... 2.0.2 Adaptive immune system2.0.2.1 Lymphocytes2.0.2.2 Killer T cells2.0.2.3 Helper T cells2.0.2.4 Gamma delta T cells2.0.2.5 B lymphocytes and antibodies2.0.3 Tumor immunology – the immune surveillance system2.1 Immuno Oncology Diagnostics 2.1.1 Checkpoint Assays2.1.2 Cytokine Assays2.1.3 Genomic Germline2.1.4 Genomic Tumour2.1.5 Tumor Microenviroment3. Industry Overview3.1 Players in a Dynamic Market3.1.1 Academic Research Lab3.1.2 Diagnostic Test Developer3.1.3 Genomic ... |
| 2/28/2021 |
Reviewing ACI Global (OTCMKTS:ACGJ) & Biocept (NASDAQ:BIOC) |
thelincolnianonline.com |
... ACI Global on 5 of the 9 factors compared between the two stocks.About ACI GlobalThere is no company description available for ACI Global Corp.About BioceptBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 2/28/2021 |
Reviewing Biocept (NASDAQ:BIOC) & ACI Global (OTCMKTS:ACGJ) |
com-unik.info |
... plainly believe Biocept is more favorable than ACI Global.SummaryBiocept beats ACI Global on 5 of the 9 factors compared between the two stocks.Biocept Company ProfileBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |
| 2/26/2021 |
Guardant Health Challenges Exact Sciences’ Leadership of Colorectal Cancer Diagnostics Market |
g2intelligence.com |
... Institute (TGen) for an undisclosed price. Ashion is a CLIA-certified and CAP-accredited sequencing lab whose genomic testing assets will bolster Exact’s efforts to enhance its Cologuard product and develop new precision oncology diagnostics for MRD and other cancers. Those Ashion assets include the GEM ExTra comprehensive cancer test, as well as whole-exome, matched germline and transcriptome sequencing capabilities.The Ashion acquisition, which is scheduled to close ... |